Key facts
as of Sep 2026- Notable investors include 5AM Ventures.
- 1 institutional filer reports fund marks on Genuiti Therapeutics across 4 filings.
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$5per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Genuiti Therapeutics
- ·The full record, as it builds
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Genuiti Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest Jan 20261 SEC-registered fund reported 4 fair-value marks on Genuiti Therapeutics between Apr 2025 and Jan 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No rounds on record
No funding rounds for Genuiti Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
Investors
1About Genuiti Therapeutics
This company is currently operating in Stealth mode.
- Sector
- Business Products and Services (B2B)
- HQ
- San Francisco, CA, United States
- Ownership
- Privately Held (backing)